Zeng Yao, Li Zishan, Lin Xiaolong
Department of Pathology, The Affiliated Huizhou Hospital (Huizhou Third People's Hospital), Guangzhou Medical University, Huizhou, Guangdong 516001, P.R. China.
Department of Cardiovascularology, The Affiliated Huizhou Hospital (Huizhou Third People's Hospital), Guangzhou Medical University, Huizhou, Guangdong 516001, P.R. China.
Biomed Rep. 2025 Jun 10;23(2):134. doi: 10.3892/br.2025.2012. eCollection 2025 Aug.
Cardiovascular diseases (CVDs) remain a leading cause of global mortality. As the burden of these diseases continues to rise, the development of innovative therapeutic agents has become increasingly important. Honokiol, a bioactive compound extracted from the bark and leaves of particular Magnolia species, has garnered attention for its wide-ranging pharmacological effects, including anti-inflammatory, antioxidant, and vasodilatory properties. Emerging research suggests that honokiol holds significant promise as a therapeutic agent for managing CVDs. The present review provides a comprehensive overview of the bioactive properties, cardiovascular effects, mechanisms of action, and potential clinical utility of honokiol for the treatment of CVDs. Furthermore, challenges and future directions for the clinical translation of honokiol are discussed at length to provide additional context.
心血管疾病(CVDs)仍然是全球死亡的主要原因。随着这些疾病负担的持续上升,创新治疗药物的开发变得越来越重要。厚朴酚是从特定木兰属植物的树皮和叶子中提取的一种生物活性化合物,因其广泛的药理作用,包括抗炎、抗氧化和血管舒张特性而受到关注。新出现的研究表明,厚朴酚作为治疗心血管疾病的药物具有巨大潜力。本综述全面概述了厚朴酚治疗心血管疾病的生物活性、心血管效应、作用机制和潜在临床应用。此外,还详细讨论了厚朴酚临床转化面临的挑战和未来方向,以提供更多背景信息。